Company / Revenue per Share
Dianthus Therapeutics, Inc. /DE/ Revenue per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Revenue per Share
$0.07
FY2025
5-year range
$0.07 / $0.55
FY2021-FY2025
Trend
-65.7%
vs FY2024
Sector context
#137 of 154
Health Care
What the data says
Dianthus Therapeutics, Inc. /DE/'s revenue per share of $0.07 is lower than 89% of companies in the Health Care sector (FY2025). Declined from $0.55 to $0.07 over the past 2 years.
Based on SEC 10-K filings.
0.07 in FY2025.
Declined from $0.55 to $0.07 over the past 2 years.
Health Care sector context is included.
Revenue per Share over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 11% in Health CareTop 89% of 154This company $0.07 Sector average $10.35
▼
-99.4% below sector average
Key checks
Key Insights
- In FY2025, revenue per share decreased 65.7% year-over-year.
- Ranks #137 out of 154 companies in the Health Care sector.
- Peak revenue per share was recorded in FY2023.
- Lowest revenue per share in the period was in FY2019.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 4.46 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Revenue per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $0.07 | -65.7% |
| FY2024 | $0.19 | -65.2% |
| FY2023 | $0.55 | - |
| FY2022 | - | - |
| FY2021 | - | - |
| FY2020 | - | - |
| FY2019 | $0.00 | - |
| FY2018 | $0.00 | - |
| FY2017 | $0.00 | - |
| FY2016 | $0.00 | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026